![]() |
市场调查报告书
商品编码
1345418
全球外周静脉导管市场 - 2023-2030Global Peripheral IV Catheters Market - 2023-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
概述
2022年,全球外周静脉导管市场规模达到52亿美元,预计到2030年将达到91亿美元,2023-2030年预测期间复合年增长率为7.4%。
外周静脉导管 (PIVC) 是最常用的静脉装置,主要用于治疗目的,例如给药、输液和血液製品。导管位置、通畅/闭塞、肢体对称性、静脉炎的任何证据(红斑、不适、肿胀、疼痛等)、压力损伤以及浸润/外渗损伤的体征均在外周静脉导管评估中进行评估。
此外,全球外周静脉导管市场受到慢性疾病患病率上升、技术进步、微创手术增加以及强劲医疗保健支出的推动,这些因素将在预测期内推动市场发展。
动力学
心血管疾病患病率上升
患有某些心血管疾病(例如心房颤动或深静脉血栓形成)的患者可能需要抗凝治疗以避免血栓。静脉 (IV) 导管可以提供肝素等抗凝药物,以维持健康的血流。心血管疾病发病率的上升是预测期内推动市场的重要驱动因素。
例如,根据美国疾病控制与预防中心更新的 2023 年情况说明书,心脏病是美国男性、女性以及大多数种族和民族群体个人的主要原因。在美国,每 33 秒就有一人死于心血管疾病。
2021 年,美国约有 695,000 人死于心脏病,占死亡人数的五分之一。 2018年至2019年,美国在心脏病方面的支出约为2399亿美元。这涵盖了医疗保健服务、药物的费用以及因死亡而造成的生产力损失。
技术进步的崛起
技术进步的增长是预测期内推动市场的关键因素之一。例如,2023 年 4 月,全球医疗技术公司 BD 推出了 BD Prevue II 系统,这是一种先进的超声设备,配有专用探头,可实现最佳 IV 放置。
该系统通过实时针深度标记解决了 IV 通路未满足的需求,并采用 BD Cue 针跟踪系统,提供针轨蹟的高质量超声图像。它与 BD Cue 针跟踪导管兼容。 BD Prevue II 系统旨在为临床医生提供最佳的静脉注射放置位置,并且易于使用。
老年人口的增加
随着人口老龄化,需要更多的医疗程序,例如静脉治疗。随着人口老龄化,对外周静脉导管提供药物和液体的需求也在不断增长。
老年人更容易出现心脏病。随着全球老年人口的增长,与年龄相关的心臟问题患病率的增加预计将增加对起搏器的需求。
例如,根据《临床心脏病学》发表的一篇文章,大约 60% 的 60 岁以上的美国人口患有高血压,导致心脏病发作,从而导致对外周静脉导管的需求增加。到2060年,65岁及以上的人口数量将达到美国总人口的25%,其中80岁以上的人口将达到200亿。
针刺损伤的增加鼓励采用外周静脉导管
对于需要频繁注射的患者来说,注射针的针刺伤是一个主要问题。处理、拆卸甚至丢弃针头和注射器可能会导致针尖造成经皮伤口损伤。据美国医学协会称,针刺在医疗保健行业中很常见。据估计,美国每年发生 60 万至 80 万起针刺伤。
例如,2022 年 7 月,输液治疗领域的领导者贝朗医疗公司 (B. Braun Medical Inc) 宣布推出具有一次性血液控制功能的新型 Introcan Safety 2 IV 导管。 Introcan Safety 2 IV 导管是 B. Braun 的最新开发产品,可降低针刺伤害和接触血液的风险,从而使临床医生的 IV 通路更加安全
与导管相关的风险和并发症
原位外周静脉导管可能会出现并发症,儘管可以通过充分的无菌操作和设备评估来避免这些并发症。感染、静脉炎、导管/液体/药物的存在以及长期不适的患者的困难都是常见的后果。当液体或药物输送到周围组织时,就会发生渗透/外渗;如果发生这种情况,请参阅外渗损伤处理护理指南。通过采用适当的无菌技术和评估可以避免这些问题。
Global Peripheral IV Catheters Market reached US$ 5.2 billion in 2022 and is expected to reach US$ 9.1 billion by 2030, growing with a CAGR of 7.4% during the forecast period 2023-2030.
Peripheral intravenous catheters (PIVCs) are the most commonly used intravenous devices which are primarily used for therapeutic purposes such as the administration of medications, fluids, and blood products. The catheter location, patency/occlusion, limb symmetry, any evidence of phlebitis (erythema, discomfort, swelling, pain, etc.), pressure injuries, and signs of infiltration/extravasation injuries are all evaluated in the assessment of peripheral IV Catheters.
Furthermore, the global peripheral IV catheter market is driven by a rise in the prevalence of chronic disorders, technological advancements, a rise in minimally invasive procedures, and strong healthcare expenditures that will drive the market during the forecast period.
Patients with certain cardiovascular conditions, such as atrial fibrillation or deep vein thrombosis, may require anticoagulation treatment to avoid blood clots. Intravenous (IV) catheters can supply anticoagulant drugs like heparin to maintain healthy blood flow. The rise in the incidence of cardiovascular diseases is the significant key driver that drives the market during the forecast period.
For instance, according to the Centres for Disease Control and Prevention's updated factsheet 2023, heart disease is the main cause of death in the United States for men, women, and individuals of most racial and ethnic groups. In the United States, one person dies from cardiovascular disease every 33 seconds.
Approximately 695,000 persons in the United States died from heart disease in 2021, accounting for one out of every five fatalities. From 2018 to 2019, the United States spent around $239.9 billion on heart disease. This covers the expense of healthcare services, medications, and lost productivity as a result of mortality.
Rise in the technological advancements is one of the key factors that drive the market during the forecast period. For instance, in April 2023, BD, a global medical technology company, launched the BD Prevue II System, an advanced ultrasound device with a specialized probe for optimal IV placement.
The system addresses the unmet need for IV access through real-time needle depth markers and features the BD Cue Needle Tracking System, providing high-quality ultrasound images of the needle trajectory. It is compatible with BD Cue Needle Tracking-enabled catheters. The BD Prevue II System is designed to provide clinicians with optimal IV placement and is easy to use.
As the population ages, more medical procedures, such as intravenous therapy, are required. The need for peripheral IV catheters to provide medicine and fluids develops in tandem with the ageing population.
The elderly are more vulnerable to heart problems. The increased prevalence of age-related cardiac problems is predicted to increase demand for pacemakers as the global geriatric population grows.
For instance according to an article published by Clinical Cardiology Around 60% of the US population over the age of 60 have hypertension, leading to heart attacks which result in increased demand for peripheral iv catheters requirement. By 2060, the number of people aged 65 and over will reach 25% of the US population, with 20 Billion beyond the eighth decade.
For patients who require frequent injections, needle stick injuries from injection needles are a major problem. Handling, disassembling, or even disposal of needles and syringes can result in percutaneous wound injuries from needle tips. According to the America Medical Association Needle sticks are a common occurrence in the healthcare profession. It is estimated that 600 000 to 800 000 needlestick injuries occur per year in the United States.
For instance, In July 2022, B. Braun Medical Inc, a leader in infusion therapy, announced the launch of its new Introcan Safety 2 IV Catheter with one-time blood control. The Introcan Safety 2 IV Catheter is the latest development from B. Braun for making IV access safer for the clinician by reducing the risk of needlestick injuries and exposure to blood
Complications of PIVC in situ can arise, although they can be avoided with adequate aseptic procedures and device evaluation. Infection, phlebitis, catheter/fluid/medication presence, and difficulties with chronically unwell patients are all common consequences. When fluids or drugs are transported into surrounding tissue, infiltration/extravasation occurs; if this occurs, see the extravasation injury management nursing guideline. These issues can be avoided by employing proper aseptic techniques and evaluation.
The Global Peripheral IV Catheters market is segmented based on product, technology, end user and region.
The integrated peripheral intravenous catheters from the product segment with around 42.5% is expected to dominate during the forecast period. People adjusting the catheter to attach the extension set cause internal pressures in the vein to be reduced with integrated peripheral intravenous catheters. Following insertion, the use of integrated catheters offers additional fluid tubing connections or direct injections conducted via the dedicated port, which is somewhat upstream of the catheter itself and limits the movement of the catheter body against the internal vein wall.
For instance, according to research published in the British Journal of Nursing in August 2022, a close/integrated catheter reduces the danger of the healthcare professional coming into touch with the patient's blood and enables the safe collection of blood samples. It can assist prevent backflow into the cannula tip, minimising the risk of obstruction and the need for several insertions. It is also critical that the device stays stable after insertion to minimise micro-movements within the vessel (which might damage the tunica intima, resulting in mechanical phlebitis.
North America is estimated to hold about 39.6% of the total market share throughout the forecast period due to launches by the key players, rising chronic diseases and a growing senior population. Also, North America has sophisticated healthcare facilities, and the reimbursement coverage contributes to the large market share of the region
For instance, in March 2022, Shockwave Medical, Inc, a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced the global commercial availability of the Shockwave M5 + peripheral IVL catheter after receiving both CE Mark and U.S. Food and Drug Administration (FDA) clearance. The Shockwave M5 + catheter, which has been in limited launch until today, is specifically designed to decrease IVL treatment time, provide alternative access options, and expand IVL therapy to patients with larger vessel sizes.
The major global players in the market include: Becton Dickinson, B. Braun Melsungen AG, Argon Medical, Vygon, ICU Medical Inc, VOGT Medical, RenovoRx Inc, Nipro Medical, Teleflex, Greiner Bio-One and among others.
Covid has a huge influence on the peripheral intravenous catheter market, which is facing substantial challenges The main issue is the difficulty to access raw materials required for the fabrication of peripheral intravenous catheters due to transportation facility issues. Furthermore, due to an increase in the number of patients suffering from COVID-19 and other life-threatening illnesses, product distributors are seeing unpredictable demand from retailers.
The Russia-Ukraine conflict had a moderate impact on the global peripheral IV catheters market, owing to the disruption of supply chains and the shortage of healthcare infrastructure where the impact directly hit on these factors. Overall, the impact of the import and export of devices is expected to have an influence on the overall global peripheral IV catheters market growth over the forecast period.
The global Peripheral IV Catheters market report would provide approximately 61 tables, 58 figures and 186 Pages.
LIST NOT EXHAUSTIVE